Tango Therapeutics R&D president sells 5,000 shares

Q: What were the terms of Crystal Adam's TNGX option exercise?

Adam exercised options for 5,000 common shares at $2.91 per share on November 2, 2026. The option was scheduled to vest and become exercisable over four years, with 25% on January 1, 2026, and the remaining shares in 36 equal monthly installments.

The option was scheduled to vest and become exercisable over four years, with 25% on January 1, 2026, then 36 equal monthly installments.

Available on EDGAR 11/04/2026 - 07:35 PM EST Accepted by SEC EDGAR 11/04/2026 - 07:35 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

At Tango Therapeutics, Inc., President, R&D Crystal Adam exercised options for 5,000 common shares on November 2, 2026, at a $2.91 exercise price. The reported option holding after the exercise was 313,090 shares. On the same date, Adam sold 3,900 shares at a weighted average $22.2617 per share and 1,100 shares at a weighted average $22.9882 per share. The transactions were made under a Rule 10b5-1 trading plan adopted June 10, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,000 shares ($98K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Crystal Adam

Role President, R&D

Sold 5,000 shs ($112K)

Approx. gross sale proceeds $112K

Approx. exercise cost $15K

Approx. pre-tax spread $98K

Share of Position Sold 4.1%

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F4}	5,000	$0.00	$0.00
Exercise	Common Stock ^F1	5,000	$2.91	$15K
Sale	Common Stock ^{F1, F2}	3,900	$22.2617	$87K
Sale	Common Stock ^{F1, F3}	1,100	$22.9882	$25K

Holdings After Transaction: Stock Option (Right to Buy) — 313,090 contracts (Direct); Common Stock — 115,743 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 318,090 to 313,090 contracts (Direct); Common Stock, 115,743 to 115,743 shares (Direct)

Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (4)

F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026.
F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.83 to $22.8299 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.84 to $23.8399 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4. This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 5,000 options Exercise price: $2.91 per share Common shares acquired on exercise: 5,000 shares +3 more

6 metrics

Options exercised 5,000 options November 2, 2026

Exercise price $2.91 per share Options exercised November 2, 2026

Common shares acquired on exercise 5,000 shares November 2, 2026

Reported option holding after exercise 313,090 shares Following the November 2, 2026 transaction

Weighted average sale price $22.2617 per share 3,900 shares sold November 2, 2026

Weighted average sale price $22.9882 per share 1,100 shares sold November 2, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sales price per share, vest and become exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"Rule 10b5-1 trading plan adopted on June 10, 2026"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

vest and become exercisable financial

"vest and become exercisable over a four-year period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TNGX shares did Crystal Adam sell, and at what prices?

Adam sold 3,900 shares at a weighted average $22.2617 per share, with sale prices ranging from $21.83 to $22.8299, and 1,100 shares at a weighted average $22.9882 per share, with prices ranging from $22.84 to $23.8399. The sales were made under a Rule 10b5-1 plan adopted June 10, 2026.

What were the terms of Crystal Adam's TNGX option exercise?

Adam exercised options for 5,000 common shares at $2.91 per share on November 2, 2026. The option was scheduled to vest and become exercisable over four years, with 25% on January 1, 2026, and the remaining shares in 36 equal monthly installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last)

(First)

(Middle)

C/O TANGO THERAPEUTICS, INC.

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON

MASSACHUSETTS

02215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/02/2026		M⁽¹⁾		5,000	A	$2.91	120,743	D
Common Stock	11/02/2026		S⁽¹⁾		3,900	D	$22.2617⁽²⁾	116,843	D
Common Stock	11/02/2026		S⁽¹⁾		1,100	D	$22.9882⁽³⁾	115,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.91	11/02/2026		M⁽¹⁾			5,000	⁽⁴⁾	02/03/2035	Common Stock	5,000	$0	313,090	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $21.83 to $22.8299 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $22.84 to $23.8399 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter.

	/s/ Julie Fogarty, as attorney-in-fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR